KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arbutus Biopharma (ABUS) EBIT Margin (2016 - 2025)

Arbutus Biopharma's EBIT Margin history spans 13 years, with the latest figure at 1636.86% for Q3 2025.

  • For Q3 2025, EBIT Margin fell 3567.0% year-over-year to 1636.86%; the TTM value through Sep 2025 reached 320.44%, up 91262.0%, while the annual FY2024 figure was 1236.74%, 80620.0% down from the prior year.
  • EBIT Margin for Q3 2025 was 1636.86% at Arbutus Biopharma, down from 13.86% in the prior quarter.
  • Across five years, EBIT Margin topped out at 13.86% in Q2 2025 and bottomed at 1636.86% in Q3 2025.
  • The 5-year median for EBIT Margin is 648.66% (2021), against an average of 723.96%.
  • The largest annual shift saw EBIT Margin tumbled -113838bps in 2024 before it soared 126432bps in 2025.
  • A 5-year view of EBIT Margin shows it stood at 648.66% in 2021, then surged by 44bps to 361.28% in 2022, then crashed by -168bps to 967.23% in 2023, then increased by 8bps to 885.2% in 2024, then crashed by -85bps to 1636.86% in 2025.
  • Per Business Quant, the three most recent readings for ABUS's EBIT Margin are 1636.86% (Q3 2025), 13.86% (Q2 2025), and 1456.86% (Q1 2025).